A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
Purpose A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H)...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2021-09, Vol.189 (2), p.455-461 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 461 |
|---|---|
| container_issue | 2 |
| container_start_page | 455 |
| container_title | Breast cancer research and treatment |
| container_volume | 189 |
| creator | Fujii, Takeo Masuda, Hiroko Cheng, Yee Chung Yang, Fei Sahin, Aysegul A. Naoi, Yasuto Matsunaga, Yuki Raghavendra, Akshara Sinha, Arup Kumar Fernandez, Jose Rodrigo Espinosa James, Anjali Yamagishi, Keisuke Matsushima, Tomoko Schuetz, Robert Tripathy, Debu Tada, Sachiyo Jackson, Rubie S. Noguchi, Shinzaburo Nakamura, Seigo Acoba, Jared D. Ueno, Naoto T. |
| description | Purpose
A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk.
Methods
Patients with ER-positive, HER2-negative, node-negative breast cancer and RS 11–25 who underwent definitive surgery and adjuvant endocrine therapy without any cytotoxic agents were included. RNA was extracted from archived formalin-fixed, paraffin-embedded samples, and 95-gene signature was calculated.
Results
206 patients had RS of 11–25 (95GC-L,
N
= 163; 95GC-H,
N
= 43). In Cox proportional hazards model, 95GC-H was significantly associated with shorter time to recurrence than was 95GC-L (HR 5.94; 95%CI 1.81–19.53;
P
= 0.005). The correlation between 95-gene signature and 21-gene signature assay scores was not strong (correlation coefficient
r
= 0.27), which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.
Conclusions
The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy. |
| doi_str_mv | 10.1007/s10549-021-06276-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2541782833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A671783446</galeid><sourcerecordid>A671783446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-7f753ab6b3d7ef28d307132dd53227fc85ed9979904f1f4c913491f1d29cc0733</originalsourceid><addsrcrecordid>eNp9kt2KFDEQhRtRcFx9Aa8CgnixWfPT3ZlcDsvoCgvCotchk67MZO1JxlR6xefyBTdji_uDSC6SKr5zqAqnaV5zdsYZU--Rs67VlAlOWS9UT9WTZsE7JakSXD1tFoz3ivZL1j9vXiBeM8a0YnrR_FoR3dEtRCAYttGWKddXybYEHwBJBjflDNEByQG_keRJiDcWww2QISBYhNog6yt6SBhKbZ-Si_WVoBG2di5jGuBvSTa5agpxtlpm8iOUXdUXyHsYgi1A6gaPprk3ArqUAV82z7wdEV79uU-arx_WX84v6OXnj5_OV5fUtbotVHnVSbvpN3JQ4MVykExxKYahk0Io75YdDForrVnruW-d5rLV3PNBaOeYkvKkeTf7HnL6PgEWsw_oYBxthDShEV3L1VIs5RF98wi9TlOOdbpK9fXzJWf9HbW1I5gQfaof7Y6mZtWr6iXb9kid_YOqZ4B9cCmCD7X_QPD2nmAHdiw7TONUQor4EBQz6HJCzODNIYe9zT8NZ-aYIzPnyNQcmd85MqqK5CzCCsct5LvV_qO6Bc-Nyk8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560163106</pqid></control><display><type>article</type><title>A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores</title><source>SpringerLink Journals - AutoHoldings</source><creator>Fujii, Takeo ; Masuda, Hiroko ; Cheng, Yee Chung ; Yang, Fei ; Sahin, Aysegul A. ; Naoi, Yasuto ; Matsunaga, Yuki ; Raghavendra, Akshara ; Sinha, Arup Kumar ; Fernandez, Jose Rodrigo Espinosa ; James, Anjali ; Yamagishi, Keisuke ; Matsushima, Tomoko ; Schuetz, Robert ; Tripathy, Debu ; Tada, Sachiyo ; Jackson, Rubie S. ; Noguchi, Shinzaburo ; Nakamura, Seigo ; Acoba, Jared D. ; Ueno, Naoto T.</creator><creatorcontrib>Fujii, Takeo ; Masuda, Hiroko ; Cheng, Yee Chung ; Yang, Fei ; Sahin, Aysegul A. ; Naoi, Yasuto ; Matsunaga, Yuki ; Raghavendra, Akshara ; Sinha, Arup Kumar ; Fernandez, Jose Rodrigo Espinosa ; James, Anjali ; Yamagishi, Keisuke ; Matsushima, Tomoko ; Schuetz, Robert ; Tripathy, Debu ; Tada, Sachiyo ; Jackson, Rubie S. ; Noguchi, Shinzaburo ; Nakamura, Seigo ; Acoba, Jared D. ; Ueno, Naoto T.</creatorcontrib><description>Purpose
A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk.
Methods
Patients with ER-positive, HER2-negative, node-negative breast cancer and RS 11–25 who underwent definitive surgery and adjuvant endocrine therapy without any cytotoxic agents were included. RNA was extracted from archived formalin-fixed, paraffin-embedded samples, and 95-gene signature was calculated.
Results
206 patients had RS of 11–25 (95GC-L,
N
= 163; 95GC-H,
N
= 43). In Cox proportional hazards model, 95GC-H was significantly associated with shorter time to recurrence than was 95GC-L (HR 5.94; 95%CI 1.81–19.53;
P
= 0.005). The correlation between 95-gene signature and 21-gene signature assay scores was not strong (correlation coefficient
r
= 0.27), which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.
Conclusions
The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-021-06276-7</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvant treatment ; Breast cancer ; Cancer ; Cancer research ; Care and treatment ; Cytotoxic agents ; Cytotoxicity ; Diseases ; Endocrine therapy ; Epidemiology ; ErbB-2 protein ; Formaldehyde ; Genes ; Genetic aspects ; Invasiveness ; Medicine ; Medicine & Public Health ; Oncology ; Paraffin ; Patients ; Relapse ; Risk factors ; RNA</subject><ispartof>Breast cancer research and treatment, 2021-09, Vol.189 (2), p.455-461</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>COPYRIGHT 2021 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-7f753ab6b3d7ef28d307132dd53227fc85ed9979904f1f4c913491f1d29cc0733</citedby><cites>FETCH-LOGICAL-c494t-7f753ab6b3d7ef28d307132dd53227fc85ed9979904f1f4c913491f1d29cc0733</cites><orcidid>0000-0002-0166-7275</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-021-06276-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-021-06276-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Fujii, Takeo</creatorcontrib><creatorcontrib>Masuda, Hiroko</creatorcontrib><creatorcontrib>Cheng, Yee Chung</creatorcontrib><creatorcontrib>Yang, Fei</creatorcontrib><creatorcontrib>Sahin, Aysegul A.</creatorcontrib><creatorcontrib>Naoi, Yasuto</creatorcontrib><creatorcontrib>Matsunaga, Yuki</creatorcontrib><creatorcontrib>Raghavendra, Akshara</creatorcontrib><creatorcontrib>Sinha, Arup Kumar</creatorcontrib><creatorcontrib>Fernandez, Jose Rodrigo Espinosa</creatorcontrib><creatorcontrib>James, Anjali</creatorcontrib><creatorcontrib>Yamagishi, Keisuke</creatorcontrib><creatorcontrib>Matsushima, Tomoko</creatorcontrib><creatorcontrib>Schuetz, Robert</creatorcontrib><creatorcontrib>Tripathy, Debu</creatorcontrib><creatorcontrib>Tada, Sachiyo</creatorcontrib><creatorcontrib>Jackson, Rubie S.</creatorcontrib><creatorcontrib>Noguchi, Shinzaburo</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Acoba, Jared D.</creatorcontrib><creatorcontrib>Ueno, Naoto T.</creatorcontrib><title>A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk.
Methods
Patients with ER-positive, HER2-negative, node-negative breast cancer and RS 11–25 who underwent definitive surgery and adjuvant endocrine therapy without any cytotoxic agents were included. RNA was extracted from archived formalin-fixed, paraffin-embedded samples, and 95-gene signature was calculated.
Results
206 patients had RS of 11–25 (95GC-L,
N
= 163; 95GC-H,
N
= 43). In Cox proportional hazards model, 95GC-H was significantly associated with shorter time to recurrence than was 95GC-L (HR 5.94; 95%CI 1.81–19.53;
P
= 0.005). The correlation between 95-gene signature and 21-gene signature assay scores was not strong (correlation coefficient
r
= 0.27), which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.
Conclusions
The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy.</description><subject>Adjuvant treatment</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Care and treatment</subject><subject>Cytotoxic agents</subject><subject>Cytotoxicity</subject><subject>Diseases</subject><subject>Endocrine therapy</subject><subject>Epidemiology</subject><subject>ErbB-2 protein</subject><subject>Formaldehyde</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Invasiveness</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Paraffin</subject><subject>Patients</subject><subject>Relapse</subject><subject>Risk factors</subject><subject>RNA</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kt2KFDEQhRtRcFx9Aa8CgnixWfPT3ZlcDsvoCgvCotchk67MZO1JxlR6xefyBTdji_uDSC6SKr5zqAqnaV5zdsYZU--Rs67VlAlOWS9UT9WTZsE7JakSXD1tFoz3ivZL1j9vXiBeM8a0YnrR_FoR3dEtRCAYttGWKddXybYEHwBJBjflDNEByQG_keRJiDcWww2QISBYhNog6yt6SBhKbZ-Si_WVoBG2di5jGuBvSTa5agpxtlpm8iOUXdUXyHsYgi1A6gaPprk3ArqUAV82z7wdEV79uU-arx_WX84v6OXnj5_OV5fUtbotVHnVSbvpN3JQ4MVykExxKYahk0Io75YdDForrVnruW-d5rLV3PNBaOeYkvKkeTf7HnL6PgEWsw_oYBxthDShEV3L1VIs5RF98wi9TlOOdbpK9fXzJWf9HbW1I5gQfaof7Y6mZtWr6iXb9kid_YOqZ4B9cCmCD7X_QPD2nmAHdiw7TONUQor4EBQz6HJCzODNIYe9zT8NZ-aYIzPnyNQcmd85MqqK5CzCCsct5LvV_qO6Bc-Nyk8</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Fujii, Takeo</creator><creator>Masuda, Hiroko</creator><creator>Cheng, Yee Chung</creator><creator>Yang, Fei</creator><creator>Sahin, Aysegul A.</creator><creator>Naoi, Yasuto</creator><creator>Matsunaga, Yuki</creator><creator>Raghavendra, Akshara</creator><creator>Sinha, Arup Kumar</creator><creator>Fernandez, Jose Rodrigo Espinosa</creator><creator>James, Anjali</creator><creator>Yamagishi, Keisuke</creator><creator>Matsushima, Tomoko</creator><creator>Schuetz, Robert</creator><creator>Tripathy, Debu</creator><creator>Tada, Sachiyo</creator><creator>Jackson, Rubie S.</creator><creator>Noguchi, Shinzaburo</creator><creator>Nakamura, Seigo</creator><creator>Acoba, Jared D.</creator><creator>Ueno, Naoto T.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0166-7275</orcidid></search><sort><creationdate>20210901</creationdate><title>A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores</title><author>Fujii, Takeo ; Masuda, Hiroko ; Cheng, Yee Chung ; Yang, Fei ; Sahin, Aysegul A. ; Naoi, Yasuto ; Matsunaga, Yuki ; Raghavendra, Akshara ; Sinha, Arup Kumar ; Fernandez, Jose Rodrigo Espinosa ; James, Anjali ; Yamagishi, Keisuke ; Matsushima, Tomoko ; Schuetz, Robert ; Tripathy, Debu ; Tada, Sachiyo ; Jackson, Rubie S. ; Noguchi, Shinzaburo ; Nakamura, Seigo ; Acoba, Jared D. ; Ueno, Naoto T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-7f753ab6b3d7ef28d307132dd53227fc85ed9979904f1f4c913491f1d29cc0733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvant treatment</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Care and treatment</topic><topic>Cytotoxic agents</topic><topic>Cytotoxicity</topic><topic>Diseases</topic><topic>Endocrine therapy</topic><topic>Epidemiology</topic><topic>ErbB-2 protein</topic><topic>Formaldehyde</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Invasiveness</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Paraffin</topic><topic>Patients</topic><topic>Relapse</topic><topic>Risk factors</topic><topic>RNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujii, Takeo</creatorcontrib><creatorcontrib>Masuda, Hiroko</creatorcontrib><creatorcontrib>Cheng, Yee Chung</creatorcontrib><creatorcontrib>Yang, Fei</creatorcontrib><creatorcontrib>Sahin, Aysegul A.</creatorcontrib><creatorcontrib>Naoi, Yasuto</creatorcontrib><creatorcontrib>Matsunaga, Yuki</creatorcontrib><creatorcontrib>Raghavendra, Akshara</creatorcontrib><creatorcontrib>Sinha, Arup Kumar</creatorcontrib><creatorcontrib>Fernandez, Jose Rodrigo Espinosa</creatorcontrib><creatorcontrib>James, Anjali</creatorcontrib><creatorcontrib>Yamagishi, Keisuke</creatorcontrib><creatorcontrib>Matsushima, Tomoko</creatorcontrib><creatorcontrib>Schuetz, Robert</creatorcontrib><creatorcontrib>Tripathy, Debu</creatorcontrib><creatorcontrib>Tada, Sachiyo</creatorcontrib><creatorcontrib>Jackson, Rubie S.</creatorcontrib><creatorcontrib>Noguchi, Shinzaburo</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Acoba, Jared D.</creatorcontrib><creatorcontrib>Ueno, Naoto T.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujii, Takeo</au><au>Masuda, Hiroko</au><au>Cheng, Yee Chung</au><au>Yang, Fei</au><au>Sahin, Aysegul A.</au><au>Naoi, Yasuto</au><au>Matsunaga, Yuki</au><au>Raghavendra, Akshara</au><au>Sinha, Arup Kumar</au><au>Fernandez, Jose Rodrigo Espinosa</au><au>James, Anjali</au><au>Yamagishi, Keisuke</au><au>Matsushima, Tomoko</au><au>Schuetz, Robert</au><au>Tripathy, Debu</au><au>Tada, Sachiyo</au><au>Jackson, Rubie S.</au><au>Noguchi, Shinzaburo</au><au>Nakamura, Seigo</au><au>Acoba, Jared D.</au><au>Ueno, Naoto T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><date>2021-09-01</date><risdate>2021</risdate><volume>189</volume><issue>2</issue><spage>455</spage><epage>461</epage><pages>455-461</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk.
Methods
Patients with ER-positive, HER2-negative, node-negative breast cancer and RS 11–25 who underwent definitive surgery and adjuvant endocrine therapy without any cytotoxic agents were included. RNA was extracted from archived formalin-fixed, paraffin-embedded samples, and 95-gene signature was calculated.
Results
206 patients had RS of 11–25 (95GC-L,
N
= 163; 95GC-H,
N
= 43). In Cox proportional hazards model, 95GC-H was significantly associated with shorter time to recurrence than was 95GC-L (HR 5.94; 95%CI 1.81–19.53;
P
= 0.005). The correlation between 95-gene signature and 21-gene signature assay scores was not strong (correlation coefficient
r
= 0.27), which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.
Conclusions
The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s10549-021-06276-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0166-7275</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2021-09, Vol.189 (2), p.455-461 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2541782833 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Adjuvant treatment Breast cancer Cancer Cancer research Care and treatment Cytotoxic agents Cytotoxicity Diseases Endocrine therapy Epidemiology ErbB-2 protein Formaldehyde Genes Genetic aspects Invasiveness Medicine Medicine & Public Health Oncology Paraffin Patients Relapse Risk factors RNA |
| title | A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A39%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%2095-gene%20signature%20stratifies%20recurrence%20risk%20of%20invasive%20disease%20in%20ER-positive,%20HER2-negative,%20node-negative%20breast%20cancer%20with%20intermediate%2021-gene%20signature%20recurrence%20scores&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Fujii,%20Takeo&rft.date=2021-09-01&rft.volume=189&rft.issue=2&rft.spage=455&rft.epage=461&rft.pages=455-461&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-021-06276-7&rft_dat=%3Cgale_proqu%3EA671783446%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560163106&rft_id=info:pmid/&rft_galeid=A671783446&rfr_iscdi=true |